The dual effect of curcumin nanoparticles encapsulated by 1-3/1-6

Tóm tắt

Curcumin is a polyphenol from turmeric Curcuma longa L that has been proved to possess numerous biological and pharmaceutical activities, including anti-cancer properties. However, curcumin has only limited clinical applications due to the aqueous insolubility characteristic that reduces its biological availability. On the other hand, using nanoparticles as drug delivery system has potential as it increases solubility of hydrophobic substances such as curcumin. Furthermore, nanoparticles can protect and control release of drug. Therefore, the objective of this project is to prepare nanoparticles by polymeric encapsulating curcumin by 1-3/1-6 β-glucan extracted from Vietnamese mushrooms to increase drug delivery efficiency and biological effect. Method of the preparation is nano-precipitation. The produced curcumin-β-glucan-nanoparticles (NanoGluCur) takes spherical shape with 60–70 nm in diameter. As expected, water solubility of curcumin increases about 180 times, from 0.6 μg ml−1 to 0.11 mg ml−1. Loading capacity of NanoGluCur is 18.16%. In vitro cytotoxicity and anti-tumor promoting effects of NanoGluCur were also investigated. Results revealed that NanoGluCur is able to inhibit the growth of two human cancer cell lines Hep-G2 and LU-1 with IC50 values of 6.82 and 15.53 mg ml−1, respectively, while free curcumin expresses the activity with IC50 values of 7.41 and 18.82 mg ml−1. At the concentration of 40 mg ml−1, NanoGluCur showed anti-tumor promoting effects in reducing tumor size by 59.93% and tumor density by 40.52%, while the percentages caused by pristine curcumin were 41.36% and 29.14%, respectively. These results demonstrated dual effect of 1-3/1-6 β-glucan encapsulated curcumin nanoparticles: higher water solubility and better in vitro anti-cancer effects compared to free curcumin and 1-3/1-6 β-glucan, expectedly. This observation can potentially open a new approach in research and manufacture of functional foods from medicinal mushrooms.

Tài liệu tham khảo

Lopez-Lazaro M 2008 Mol. Nutr. Food Res. 52 S103 Suppl 1
Ruby A J, Kuttan G, Babu K D, Rajasekharan K N and Kuttan R 1995 Cancer Lett. 94 79
Srimal R C and Dhawan B N 1973 J. Pharm. Pharmacol. 25 447
Mahady G B, Pendland S L, Yun G and Lu Z Z 2002 Anticancer Res. 22 4179
Barthelemy S, Vergnes L, Moynier M, Guyot D, Labidalle S and Bahraoui E 1998 Res. Virol. 149 43
Sui Z, Salto R, Li J, Craik C and Ortiz de Montellano P R 1993 Bioorg. Med. Chem. 1 415
Nguyen H N, Ha P T, Sao Nguyen A, Nguyen D T, Do H D, Thi Q N and Thi M N H 2016 Adv. Nat. Sci.: Nanosci. Nanotechnol. 7 025001
Kurien B T, Singh A, Matsumoto H and Scofield R H 2007 Assay Drug Developt. Technol. 5 567
Pan K, Zhong Q and Baek S J 2013 J. Agricult. Food Chem. 61 6036
Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A and Maitra A 2007 J. Nanobiotechnol. 5 1
Rondanelli M, Opizzi A and Monteferrario F 2009 Minerva Medica 100 237
Chan G C F, Chan W K and Sze D M Y 2009 J. Hematol. Oncol. 2 1
Yadomae T 2000 J. Pharm. Soc. Japan 120 413
Gutiérrez A, Prieto A and Martínez A T 1996 Carbohyd. Res. 281 143
Zhang M, Cui S W, Cheung P C K and Wang Q 2007 Trends Food Sci. Tech. 18 4
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren J T, Bokesch H, Kenney S and Boyd M R 1991 Eur.n J. Cancer 27 1162
Likhitayawuid K, Angerhofer C K, Cordell G A, Pezzuto J M and Ruangrungsi N 1993 J. Nat. Prod. 56 30
Kim J B 2005 Seminar in Cancer Biology 15 365
Gao H, Hou B, Kuroyanagi M and Wu L 2007 Biol. Pharm. Bulletin 25 1241
Olmsted S S, Padgett J L, Yudin A I, Whaley K J, Moench T R and Cone R A 2001 Biophys. J. 81 1930
Desai M P, Labhasetwar V, Amidon G L and Levy R J 1996 Pharm. Res. 13 1838
Fang J, Nakamura H and Maeda H 2011 Adv. Drug Delivery Rev. 63 136